Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (7210)	10/21/2002 10:28:29 PM
From: Biomaven	Respond to of 52153

Well the Massachusetts securities regulators have never lived down the fact that they successfully protected individual Massachusetts investors from making money in Apple's blue-chip underwritten IPO on the grounds that it was too risky. Separating investment banking from the stock research arm might well mean little or no money for stock research. This might hit biotech particularly hard given that many investors avoid biotechs that are thinly covered (or not covered at all). The other thing that might happen is that all the good analysts end up running hedge funds instead of working for brokers. Peter